Companion Society Meetings
Society for Hematopathology
New and Updated Entities in the Revised WHO Classification
Sunday, March 18, 2018, 1:30 - 5:00 PM
3 CME and 3 SAMs
Robert P. Hasserjian, MD, Massachusetts General Hospital, Boston, MA
Olga K. Weinberg, MD, Children's Hospital, Boston, MA
With increasing recognition of newly identified molecular features, the 2016 revision to the WHO classification includes several changes in the myeloid and lymphoid categories, with improved characterization of diseases. Growing data has become available on recurring mutations and pattern of co-mutations in many hematopoietic neoplasms that has allowed recognition of new entities and refined the diagnostic criteria of existing entities. Among myeloid neoplasms, newly discovered molecular genetic abnormalities have resulted in a new myeloid/lymphoid neoplasm disease entity associated with PCM1-JAK2 rearrangement and have enhanced our understanding of myelodysplastic syndromes with ring sideroblasts. Recognition of myeloid neoplasms occurring in the background of germline predisposing mutations is also emphasized in the revision and a new disease category has been created to encompass this group. Among the lymphomas, there has been clarification of certain lymphoma subtypes that most commonly occur in the pediatric population, but can also occur in adults, including pediatric-type follicular lymphoma and large B-cell lymphoma with IRF4 rearrangement. The classification has refined the definitions of high-grade B-cell lymphomas related to Burkitt lymphoma. In addition, a new grouping of T-follicular helper lymphomas has been introduced and concept of ALK-negative anaplastic large cell lymphoma has been solidified by the recognition of several associated genetic lesions and a specific clinicopathologic entity of breast implant-associated anaplastic large cell lymphoma. Finally, several indolent T, NK, and B-cell lymphoid proliferations that are not considered equivalent to lymphoma have been recognized. The goal of this education session is to highlight and increase the awareness of new entities as well as diseases with refined definitions in the revised WHO classification.
Upon completion of this educational activity, the learner will be able to:
- Recognize the genetic features of and correctly diagnose pediatric-type follicular lymphoma and large B-cell lymphoma with IRF4 rearrangement
- Understand how to identify germline predisposition states in patients presenting with myeloid neoplasms
- Describe the genetics and pathogenesis of myelodysplastic syndrome with ring sideroblasts
- Accurately distinguish between chronic eosinophilic leukemia, hypereosinophilic syndrome, myeloid/lymphoid neoplasms with PCM1-JAK2, and other genetically-defined eosinophilias
- Accurately diagnose Burkitt lymphoma, high-grade B-cell lymphomas (with or without double-hit), and Burkitt-like lymphoma with 11q aberrations
- Understand the spectrum of peripheral T-cell lymphomas with T follicular helper phenotype and ALK-negative anaplastic large cell lymphomas
|1:30 PM||Pediatric-type Follicular Lymphoma and Large B-cell Lymphoma with IRF4 Rearrangement
Abner Louissaint, MD, PhD, Massachusetts General Hospital, Boston, MA
|2:00 PM||Burkitt Lymphoma and Related Entities
Reiner Siebert, MD, University Hospital of Ulm, Ulm, Germany
|2:30 PM||New Concepts in Peripheral T-cell Lymphomas
Andrew Feldman, MD, Mayo Clinic, Rochester, MN
|3:30 PM||Myeloid Neoplasms with Germline Predisposition
Katherine Calvo, MD, PhD, National Institutes of Health, Bethesda, MD
|4:00 PM||Myelodysplastic Syndrome with Ring Sideroblasts
Luca Malcovati, MD, University of Pavia, Pavia, Italy
|4:30 PM||Eosinophilic Myeloid Neoplasms
Sa A Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
Continuing Medical Education and Maintenance of Certification
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The United States and Canadian Academy of Pathology and Society for Hematopathology. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of
3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 3 SAM credit hours.